353 related articles for article (PubMed ID: 19471115)
21. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
[TBL] [Abstract][Full Text] [Related]
22. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
24. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
25. NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.
Dokouhaki P; Schuh NW; Joe B; Allen CA; Der SD; Tsao MS; Zhang L
Eur J Immunol; 2013 Dec; 43(12):3175-82. PubMed ID: 24019170
[TBL] [Abstract][Full Text] [Related]
26. γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.
Janssen A; Villacorta Hidalgo J; Beringer DX; van Dooremalen S; Fernando F; van Diest E; Terrizi AR; Bronsert P; Kock S; Schmitt-Gräff A; Werner M; Heise K; Follo M; Straetemans T; Sebestyen Z; Chudakov DM; Kasatskaya SA; Frenkel FE; Ravens S; Spierings E; Prinz I; Küppers R; Malkovsky M; Fisch P; Kuball J
Cancer Immunol Res; 2020 Apr; 8(4):530-543. PubMed ID: 32019779
[TBL] [Abstract][Full Text] [Related]
27. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
29. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
Zheng J; Guo Y; Ji X; Cui L; He W
Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
[TBL] [Abstract][Full Text] [Related]
30. Systemic β-Adrenergic Receptor Activation Augments the
Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
Front Immunol; 2019; 10():3082. PubMed ID: 32038628
[TBL] [Abstract][Full Text] [Related]
31. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells.
Siegers GM; Dhamko H; Wang XH; Mathieson AM; Kosaka Y; Felizardo TC; Medin JA; Tohda S; Schueler J; Fisch P; Keating A
Cytotherapy; 2011 Jul; 13(6):753-64. PubMed ID: 21314241
[TBL] [Abstract][Full Text] [Related]
32. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
33. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
34. Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations.
Hunter S; Willcox CR; Davey MS; Kasatskaya SA; Jeffery HC; Chudakov DM; Oo YH; Willcox BE
J Hepatol; 2018 Sep; 69(3):654-665. PubMed ID: 29758330
[TBL] [Abstract][Full Text] [Related]
35. Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept.
Almeida AR; Correia DV; Fernandes-Platzgummer A; da Silva CL; da Silva MG; Anjos DR; Silva-Santos B
Clin Cancer Res; 2016 Dec; 22(23):5795-5804. PubMed ID: 27307596
[TBL] [Abstract][Full Text] [Related]
36. Anti-metastatic potential of human Vδ1(+) γδ T cells in an orthotopic mouse xenograft model of colon carcinoma.
Devaud C; Rousseau B; Netzer S; Pitard V; Paroissin C; Khairallah C; Costet P; Moreau JF; Couillaud F; Dechanet-Merville J; Capone M
Cancer Immunol Immunother; 2013 Jul; 62(7):1199-210. PubMed ID: 23619975
[TBL] [Abstract][Full Text] [Related]
37. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
38. CD27(-)CD45(+) γδ T cells can be divided into two populations, CD27(-)CD45(int) and CD27(-)CD45(hi) with little proliferation potential.
Odaira K; Kimura SN; Fujieda N; Kobayashi Y; Kambara K; Takahashi T; Izumi T; Matsushita H; Kakimi K
Biochem Biophys Res Commun; 2016 Sep; 478(3):1298-303. PubMed ID: 27553282
[TBL] [Abstract][Full Text] [Related]
39. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.
Correia DV; d'Orey F; Cardoso BA; Lança T; Grosso AR; deBarros A; Martins LR; Barata JT; Silva-Santos B
PLoS One; 2009 May; 4(5):e5657. PubMed ID: 19479075
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]